NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges - NuCana ( NASDAQ:NCNA )

3 days ago

On Saturday, NuCana plc NCNA presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with Merck & Co Inc's MRK Keytruda ( pembrolizumab ) for metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.

Ticker	Sentiment	Impact
NCNA	Neutral	36 %